AUS
NZ
UK
CA
USA
IND
Highlights
- Recruitment begins for the first paediatric patient in a pivotal kidney disease trial.
- 19 specialist sites across multiple countries involved in the paediatric study plan.
- Interim data anticipated in August; full recruitment expected by late Q3.
Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has achieved a significant milestone by enrolling its first paediatric participant in the Phase 3 ACTION3 clinical trial. This global study aims to evaluate the safety and efficacy of DMX-200 for children aged 12 to 17 diagnosed with focal segmental glomerulosclerosis (FSGS), a critical condition leading to kidney failure.
The recruitment marks a major advancement in Dimerix's journey toward addressing an unmet medical need for paediatric patients with FSGS. Currently, effective treatment options for this debilitating disease are limited, making this study a crucial step toward a new potential therapy.
The dosage administered to participating children will align with that of adult trials, leveraging interim safety and pharmacokinetic data collected earlier. These findings are expected to support regulatory approval processes with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Dr. David Fuller, Chief Medical Officer of Dimerix, emphasized the importance of this development: “Recruiting the first paediatric patient is a pivotal moment as we strive to provide a potential treatment option for young patients with FSGS.”
The first recruitment was finalized at a specialist site in Manchester, U.K., with plans to engage 19 paediatric-focused clinical trial sites across Argentina, Mexico, the United Kingdom, and the United States. If successful, the study could pave the way for broader market approvals, expanding treatment accessibility to younger patients in key global regions like the U.S. and Europe.
The ACTION3 trial's timeline includes the release of interim data by August, while full recruitment is projected to complete by the late third quarter of this year. With a combination of international collaboration and scientific innovation, this trial represents an important stride in Dimerix's efforts to combat a rare and severe disease that impacts both adults and children worldwide.
By addressing the challenges in paediatric FSGS management, Dimerix underscores its commitment to improving outcomes for underserved patient groups through groundbreaking research and development.
